PA-824 exhibits time-dependent activity in a murine model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 239-245

  Ahmad, Zahoor ^a   Peloquin, Charles A ^b   Singh, Rajendra P ^b   Derendorf, Hartmut ^b   Tyagi, Sandeep ^a   Ginsberg, Ann ^c   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MICE; NITROIMIDAZOLES; TUBERCULOSIS;

EID: 78650642282     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00849-10     Document Type: Article

References (33)

1. Ahmad, Z., E. L. Nuermberger, R. Tasneen, M. Pinn, K. Williams, J. Grosset, and P. C. Karakousis. 2010. Comparison of the "Denver regimen" against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65:729-734.
2. Balganesh, T. S., P. M. Alzari, and S. T. Cole. 2008. Rising standards for tuberculosis drug development. Trends Pharmacol. Sci. 29:576-581.
3. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
4. Craig, W. A. 2001. Does the dose matter? Clin. Infect. Dis. 33:S233-S237.
5. Diacon, A. H., R. Dawson, M. Hanekom, et al. 2010. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54:3402-3407.
6. Diacon, A. H., R. F. Patientia, A. Venter, P. D. van Helden, P. J. Smith, H. McIlleron, J. S. Maritz, and P. R. Donald. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996.
7. Donald, P. R., F. A. Sirgel, F. J. Botha, H. I. Seifart, D. P. Parkin, M. L. Vandenplas, et al. 1997. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156:895-900.
8. Ginsberg, A. M., M. W. Laurenzi, D. J. Rouse, K. D. Whitney, and M. K. Spigelman. 2009. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53:3720-3725.
9. Ginsberg, A. M., M. W. Laurenzi, D. J. Rouse, K. D. Whitney, and M. K. Spigelman. 2009. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob. Agents Chemother. 53:3726-3733.
10. Gumbo, T., A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 51: 2329-2336.
11. Holford, N. H. G., and L. B. Sheiner. 1981. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6:429-453.
12. Hu, Y., A. R. Coates, and D. A. Mitchison. 2008. Comparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 12:69-73.
13. Hyatt, J. M., P. S. McKinnon, G. S. Zimmer, and J. J. Schentag. 1995. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin. Pharmacokinet. 28:143-160.
14. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, et al. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
15. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, et al. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
16. Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
17. Lenaerts, A. J., V. Gruppo, K. S. Marietta, et al. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301.
18. MacGowan, A. P., R. Reynolds, A. R. Noel, and K. E. Bowker. 2009. Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints. Antimicrob. Agents Chemother. 53:5181-5184.
19. Manjunatha, U., H. I. Boshoff, and C. E. Barry. 2009. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2:215-218.
20. Matsumoto, M., H. Hashizume, T. Tomishige, et al. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3:2131-2144.
21. Mouton, J. W., and A. A. Vinks. 2005. Pharmacokinetic/pharmacodynamic modeling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin. Pharmacokinet. 44:201-210.
22. Nuermberger, E., and J. H. Grosset. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255.
23. Nuermberger, E., I. Rosenthal, S. Tyagi, K. N. Williams, D. Almeida, C. A. Peloquin, W. R. Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50:2621-2625.
24. Nuermberger, E., S. Tyagi, R. Tasneen, K. N. Williams, D. Almeida, I. Rosenthal, and J. H. Grosset. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524.
25. Peloquin, C. A. 2001. Pharmacological issues in the treatment of tuberculosis. Ann. N. Y. Acad. Sci. 953:157-164.
26. Peloquin, C. A. 2003. what is the 'right' dose of rifampin? Int. J. Tuberc. Lung Dis. 7:3-5.
27. Peloquin, C. A., G. S. Jaresko, C. L. Yong, A. C. Keung, A. E. Bulpitt, and R. W. Jelliffe. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679.
28. Rosenthal, I. M., M. Zhang, K. N. Williams, et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344.
29. Singh, R., U. Manjunatha, H. I. Boshoff, et al. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395.
30. Stover, C. K., P. Warrener, D. R. VanDevanter, et al. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966.
31. Tasneen, R., S. Tyagi, K. Williams, J. H. Grosset, and E. Nuermberger. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:3664-3668.
32. Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.
33. Williams, K. N., C. K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J. H. Grosset, and E. Nuermberger. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.